HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, June 8, 2022 (HealthDay News) -- Diabetes may increase the risk for long COVID symptoms fourfold, according to research presented at the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.
Jessica Harding, Ph.D., from the Emory University School of Medicine in Atlanta, and colleagues performed a scoping review of the literature to assess whether diabetes is a risk factor for postacute sequelae of COVID-19 (PASC). The analysis included seven peer-reviewed, full-text observational research studies published in English between Jan. 1, 2020, and Jan. 27, 2022, that reported on the risk for PASC in people with and without diabetes with a minimum of four weeks of follow-up after COVID-19 diagnosis.
The researchers report that 43 percent of studies identified diabetes as a potent risk factor for PASC. However, studies were heterogeneous with regard to PASC definitions (e.g., ongoing symptoms of fatigue, cough, dyspnea, etc.), populations at risk (hospitalized versus nonhospitalized), and follow-up times (range, four weeks to seven months).
"As time goes on, we are seeing the negative impacts that long COVID has on the daily lives of patients. Though more research is needed, we now know that patients with diabetes are at a disproportionate risk of long COVID and that these patients should be closely monitored," Harding said in a statement. "Careful monitoring of glucose levels in at-risk individuals may help to mitigate excess risk and reduce the burden of lingering symptoms that inhibit their overall well-being."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Published on June 08, 2022